This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E76.2 | Special Copayment Reduction: V117 | Coverage period: 5 years |
| B. Synonyms | Morquio(-like) (classic) syndrome, MPS IVA (GALNS deficiency — most common), MPS IVB (GLB1 deficiency — rare). Both subtypes fall under E76.2 |
| C. Adult onset | Likelihood of first presentation in adulthood low — symptoms usually appear at 1–3 years of age and diagnosis is made in childhood; mild forms can survive into adulthood and diagnosis may be delayed |
| Section | Summary |
|---|---|
| 1. History | Described independently by Morquio (Luis) and Brailsford in 1929. Enzyme deficiency of type IVA identified in 1974. Elosulfase alfa approved by the FDA in 2014. |
| 2. Causes | Mutations in the GALNS (IVA) or GLB1 (IVB) gene cause deficiency of N-acetylgalactosamine-6-sulfatase or beta-galactosidase, respectively. Keratan sulfate accumulation. |
| 3. Genetics | GALNS: 16q24.3 (autosomal recessive). GLB1: 3p22.3 (autosomal recessive). More than 200 variants reported in IVA. Genotype-phenotype correlation incomplete. |
| 4. General epidemiology | MPS IVA about 0.22–1.32 per 100,000 births. Regional differences exist. IVB is much rarer. No sex difference. |
| 5. Pathophysiology | Deficiency of GAG-degrading enzyme → lysosomal accumulation of keratan sulfate and chondroitin-6-sulfate → preferential involvement of cartilage and skeleton → central nervous system damaged by secondary compression. |
| 6. Symptoms | Severe short stature, spinal deformity (kyphosis, scoliosis), chest deformity, joint laxity, corneal clouding. Normal intelligence. Respiratory impairment and cervical spine compression are the main complications. |
| 7. Signs | Short stature, chest deformity, kyphosis, genu valgum, flat feet, dental enamel defects. Atlantoaxial instability (odontoid hypoplasia) is a risk factor for neural compression. |
| 8. Screening | Screening by quantification and electrophoresis of urinary keratan sulfate. DBS-based GALNS enzyme activity measurement. Note that urinary KS may normalize with increasing age. |
| 9. Diagnosis | Measurement of leukocyte GALNS or GLB1 enzyme activity is the gold standard. Confirmed by GALNS and GLB1 gene analysis. Radiologic examination (dysostosis multiplex) also used adjunctively. |
| 10. Treatment | MPS IVA: elosulfase alfa (Vimizim) ERT once weekly. Early surgical spinal fixation is essential for atlantoaxial instability. Multidisciplinary supportive care in parallel. |
| 11. Prognosis | In the severe form, death before the 20s–30s. Causes of death are atlantoaxial instability, cervical spine compression and respiratory failure. The mild form survives into adulthood. ERT expected to improve walking. |
| 12. Prevention | Genetic counseling, carrier testing (autosomal recessive), prenatal and preimplantation genetic diagnosis. Newborn screening allows early start of treatment. |
| 13. References | 10 recent references (with PMID/DOI) |
The history of Morquio syndrome dates back to 1929. The Uruguayan pediatrician Luis Morquio and the British radiologist James Brailsford independently published in journals pediatric cases showing severe short stature, spinal deformity, corneal clouding and hearing loss. Morquio described four siblings from the same family in Uruguay, and Brailsford described a patient in Birmingham, England; the two descriptions were recognized as the same disease and named Morquio-Brailsford syndrome, later shortened to Morquio syndrome.
As the mechanisms of lysosomal storage diseases were elucidated over the 1960s–70s, Singh et al. first reported in 1974 that N-acetylgalactosamine-6-sulfatase (GALNS) is the deficient enzyme in MPS IVA. MPS IVB was subsequently confirmed to be a different genetic form caused by deficiency of beta-galactosidase, encoded by the GLB1 gene. In 1994 the GALNS gene was cloned, laying the foundation for molecular diagnosis, and hundreds of pathogenic GALNS variants have since been identified.
In terms of treatment, elosulfase alfa (Vimizim; BioMarin Pharmaceutical) received FDA approval in 2014, introducing the first ERT for MPS IVA into clinical practice. Until then, symptomatic treatment and orthopedic surgery were the only management methods, but the introduction of ERT has contributed to improved walking ability and pulmonary function. Currently, the optimal timing of surgery for atlantoaxial instability, the long-term effects of ERT, development of gene therapy and other topics are being actively studied.
MPS IV is divided into two genetically distinct forms. MPS IVA is caused by deficiency of the enzyme N-acetylgalactosamine-6-sulfatase (galactose-6-sulfate sulfatase, GALNS) due to GALNS gene mutations, and MPS IVB is caused by deficiency of lysosomal beta-galactosidase 1 due to GLB1 gene mutations. MPS IVA accounts for most (about 95%) of MPS IV.
The GALNS enzyme removes sulfate groups from galactose-6-sulfate and N-acetylgalactosamine-6-sulfate residues during the degradation of keratan sulfate (KS) and chondroitin-6-sulfate (C6S). The GLB1 enzyme (beta-galactosidase) hydrolyzes galactose residues at another step of KS degradation. When either enzyme is deficient, KS and C6S progressively accumulate in lysosomes.
The characteristic pathology of MPS IV, unlike other MPS types, is that GAG accumulation is prominent in cartilage and bone tissue and mainly skeletal abnormalities appear without direct central nervous system involvement. Preservation of normal cognitive function is an important difference from the severe forms of MPS I and II. Neurologic complications arise mainly through secondary mechanisms, such as cervical spinal cord compression due to atlantoaxial instability and respiratory muscle weakness due to chest deformity.
The GALNS gene is located on the long arm of chromosome 16 at position 24.3 (16q24.3) and consists of 14 exons. The encoded GALNS protein is a lysosomal sulfatase of 522 amino acids. The GLB1 gene is located on the short arm of chromosome 3 at position 22.3 (3p22.3) and consists of 16 exons. Both genes follow an autosomal recessive mode of inheritance.
More than 200 pathogenic variants have been reported in MPS IVA (GALNS mutations). Missense variants are the most common, followed by nonsense variants, splicing variants and small insertions/deletions. MPS IVB (GLB1 mutations) is much rarer, and GLB1 variants show diverse phenotypes from the same gene, which also causes GM1 gangliosidosis. In MPS IVB, GLB1 variants tend to be located mainly in specific functional domains involved in KS degradation, producing a phenotype with only skeletal abnormalities and no nervous system involvement.
Genotype-phenotype correlation in MPS IVA is incomplete. When both alleles carry complete loss-of-function variants (nonsense, large deletions), a severe phenotype is likely, and missense variants that retain some residual enzyme activity are often associated with a mild phenotype. The carrier frequency is estimated at about 1/100–1/200.
The worldwide birth prevalence of MPS IVA is about 0.22–1.32 per 100,000 births, with considerable variation by region and ethnicity. It is reported at about 0.5 per 100,000 in British Columbia, Canada, 1.32 in Northern Ireland and 0.22 in the Netherlands and Portugal. In some ethnic groups, high frequencies of specific variants due to a founder effect are observed. There is no difference in occurrence by sex (autosomal recessive inheritance).
MPS IVB is much rarer, with only a few dozen cases reported worldwide. In Korea, national prevalence data on MPS IV are insufficient, but the number of patients is being tracked through Special Copayment Reduction registration. The number of patients with MPS IVA worldwide is estimated at about several thousand, and orphan drug status granted in countries with rare disease designation is improving access to ERT.
The pathophysiology of MPS IV is the progressive lysosomal accumulation of keratan sulfate (KS) and chondroitin-6-sulfate (C6S). When stepwise degradation of these GAGs is blocked by GALNS or GLB1 enzyme deficiency, undegraded chains accumulate in lysosomes. Unlike other MPS types, in MPS IV KS and C6S are abundantly distributed mainly in cartilage, skeleton, cornea, heart valves and so on, so GAG accumulation is prominent in these tissues.
KS accumulation in cartilage causes growth plate abnormalities, impaired cartilage maturation and defective subchondral bone formation, producing marked short stature and the skeletal findings of dysostosis multiplex. In the spine, vertebral body dysplasia, atlantoaxial instability (AAI) and kyphosis/scoliosis develop. Atlantoaxial instability in particular is the most serious complication of MPS IVA; hypoplasia of the odontoid process combined with laxity due to GAG deposition in surrounding ligaments and soft tissues causes cervical spinal cord compression.
In the respiratory system, chest deformity (pectus excavatum, thoracic narrowing) causes weakening of the respiratory apparatus and reduced pulmonary function, and GAG deposition in airway cartilage and soft tissue worsens upper airway obstruction. In the heart valves, thickening and dysfunction of the mitral and aortic valves occur. In the eye, KS deposits in the corneal stroma and causes corneal clouding. Because there is generally no direct GAG deposition in the cerebral parenchyma, cognitive function is mostly preserved as normal.
Patients with MPS IV are generally normal at birth, but growth retardation and skeletal abnormalities become apparent from about 1–3 years of age. The most prominent symptom is severe short stature, with adult height often reaching only 80–120 cm in the severe form of MPS IVA and 130–150 cm in the mild form. Spinal deformity (kyphosis, scoliosis) progresses from early on, and chest deformity (pectus carinatum, pectus excavatum) causes respiratory impairment.
Joint laxity is characteristic, so unlike other MPS types, hyperlaxity rather than joint contracture is present, particularly marked in the knee, ankle and wrist joints. Genu valgum (knock knees) and pes planus are commonly observed. Corneal clouding is mild to moderate and can cause visual decline. Dental enamel defects and widely spaced teeth are characteristic oral findings. Preservation of normal intelligence is an important difference from the severe forms of MPS I and II.
Respiratory symptoms include chronic airway obstruction, sleep apnea and recurrent upper respiratory infections. When cervical spinal cord compression due to atlantoaxial instability progresses, lower limb paralysis, gait disturbance and bladder and bowel dysfunction may occur. Heart valve abnormalities (mitral and aortic regurgitation) may occur, and hepatosplenomegaly is relatively mild compared with other MPS types. Hearing loss is also commonly present.
The most prominent sign on physical examination is severe short stature. Short-trunk dwarfism is characteristic, with a short neck and a flattened, deformed chest. Skull size is relatively normal or slightly large, and coarse facies are milder than in other MPS types. In the eyes, corneal clouding is confirmed by slit-lamp examination, and visual acuity testing and regular ophthalmologic follow-up are recommended.
Spinal radiographs show ovoid deformity of the vertebral bodies (ovoid vertebrae), generalized vertebral body dysplasia and kyphosis/scoliosis. Cervical flexion-extension radiographs are essential to evaluate the atlantoaxial relationship. If hypoplasia or absence of the odontoid process is confirmed, evaluation of cervical spinal cord compression by MRI must be done urgently. Hand radiographs show carpal bone dysplasia and enlarged metacarpal bases (proximal pointing metacarpals).
Joint examination confirms multiple joint hyperlaxity. Genu valgum deformity and flat feet cause gait abnormalities. Inspection of the chest shows pectus excavatum or pectus carinatum. Oral examination characteristically shows dental enamel defects and widened tooth spacing. Hearing tests confirm mixed conductive and sensorineural hearing loss. Urine GAG testing shows increased KS, but because urinary KS excretion may decrease to the normal range with increasing age, caution is needed for false negatives in older patients.
Screening for MPS IV begins with clinical suspicion based on clinical symptoms (short stature, spinal deformity, joint laxity). Increased keratan sulfate (KS) on urine GAG testing is an important clue. However, because urinary KS excretion tends to decrease with age, it should be noted that urinary KS may be in the normal range in older patients with MPS IV (particularly adults). For this reason, when clinical suspicion is high, it is preferable to proceed directly to enzyme activity measurement and gene analysis.
Urine GAG electrophoresis confirms an increase in the band pattern corresponding to KS. Serum KS quantification is also used to support diagnosis. DBS-based GALNS enzyme activity measurement is being used to detect MPS IVA in newborn screening studies and is included in some countries in multi-enzyme panel newborn screening for lysosomal storage diseases. In Korea, a stepwise diagnostic process (urine GAG → enzyme activity → gene analysis) is mainly used for clinically suspected patients. In newborns with a family history, early diagnosis is possible by gene analysis immediately after birth.
MPS IV is confirmed by measurement of GALNS or GLB1 enzyme activity and analysis of the GALNS and GLB1 genes.
Severe short stature (short-trunk type), spinal deformity, joint laxity, corneal clouding, dental enamel defects and normal intelligence form the clinical combination suggesting MPS IV. Radiologic findings (dysostosis multiplex, ovoid vertebral deformity, atlantoaxial instability) provide strong evidence for the diagnosis.
Increased KS is confirmed by urinary KS quantification (creatinine-corrected) and electrophoresis (age correction essential). GALNS enzyme activity is measured in leukocytes or fibroblasts to confirm MPS IVA, and GLB1 enzyme activity is measured to confirm MPS IVB. When measuring GALNS activity, the activity of other sulfatases that use the same substrate (e.g., arylsulfatase B) is also checked at the same time to exclude multiple sulfatase deficiency.
Pathogenic variants are identified by full sequencing of the GALNS or GLB1 gene (NGS panel or Sanger). Genotype information is used for phenotype prediction, confirmation of carriers in the family and prenatal diagnosis. Large deletions are confirmed by MLPA. Radiologic examinations (spine, wrist and chest radiographs, cervical flexion-extension radiographs) and brain and cervical spine MRI are used adjunctively to evaluate complications.
In MPS IVA, ERT and orthopedic surgery form the main pillars of treatment, with multidisciplinary symptomatic treatment in parallel. For MPS IVB there is currently no specific treatment, so it relies on symptomatic treatment.
Elosulfase alfa (Vimizim; BioMarin Pharmaceutical) is a recombinant human GALNS that received FDA approval in 2014. It is given intravenously at 2 mg/kg once weekly over about 4 hours. Randomized controlled trials demonstrated improvement in 6-minute walk distance and stair-climbing ability. In long-term follow-up, it has been reported to contribute to maintaining pulmonary function and walking ability. However, because skeletal abnormalities that have already progressed (spinal deformity, atlantoaxial instability) are not reversed by ERT, combination with surgery is important.
Atlantoaxial instability is the most lethal complication of MPS IVA and should be evaluated early after diagnosis with cervical flexion-extension radiographs and MRI. If odontoid hypoplasia and instability are confirmed, cervical fixation (cervical fusion) should be performed early; surgical delay increases the risk of cervical spinal cord compression and quadriplegia. Stepwise orthopedic management is needed for thoracolumbar scoliosis and kyphosis. Hip and knee corrective surgery and flatfoot correction are also performed according to indications.
This includes respiratory management (positive airway pressure for sleep apnea, respiratory rehabilitation), regular cardiac monitoring, hearing aids, ophthalmologic follow-up (corneal clouding, vision), physical and occupational therapy, and education on the use of assistive devices for short stature. During anesthesia for surgery, collaboration with anesthesiology and neurosurgery teams experienced in protecting the cervical spine given atlantoaxial instability is essential.
The prognosis of MPS IVA varies greatly with clinical severity and whether complications are managed. In the severe form, cervical spinal cord compression due to atlantoaxial instability and respiratory failure are the main causes of death, and without appropriate surgical treatment many die before the 20s–30s. The largest share of causes of death is cervical spinal cord injury due to atlantoaxial instability and reduced respiratory function.
In patients receiving active multidisciplinary treatment such as early cervical fixation, ERT and respiratory management, the prognosis improves considerably. ERT (Vimizim) has been reported to contribute to maintaining walking ability and preserving pulmonary function. In the mild form, many cases survive into adulthood, and some cases of survival into the 40s–50s or beyond have been reported. However, quality of life is reduced by cumulative complications such as joint laxity, progression of spinal deformity, heart valve abnormalities and hearing loss, and ongoing medical support is needed. The mostly preserved normal cognitive function is a characteristic prognostic advantage of MPS IV.
Because MPS IV is an autosomal recessive genetic disease, prevention strategies are similar to those for MPS I. In genetic counseling, the recurrence risk (25%) is explained to families of a child with MPS IV, and carrier status is confirmed by GALNS (or GLB1) gene analysis of both parents. Because carrier enzyme activity may overlap with the normal range, molecular genetic testing is essential.
Prenatal diagnosis is made by measurement of fetal GALNS enzyme activity and gene analysis via CVS (10–12 weeks of gestation) or amniocentesis (15–18 weeks of gestation). Preimplantation genetic testing (PGT-M) can be used in carrier couples choosing IVF to select and transfer embryos that do not carry the pathogenic variants. The introduction of newborn screening is expected to have a secondary prevention effect through early diagnosis and early start of ERT and cervical spine management. In MPS IVA in particular, early detection of atlantoaxial instability and decisions on the timing of surgery are decisive for prognosis, so early diagnosis has great clinical significance.